Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month High at $64.79

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) reached a new 52-week high during trading on Thursday . The stock traded as high as $64.79 and last traded at $62.43, with a volume of 1115596 shares. The stock had previously closed at $58.19.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on JANX shares. Cantor Fitzgerald initiated coverage on shares of Janux Therapeutics in a research note on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 price objective for the company. Jonestrading assumed coverage on Janux Therapeutics in a report on Tuesday, April 16th. They issued a “buy” rating and a $70.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. BTIG Research initiated coverage on shares of Janux Therapeutics in a research report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $53.00 price objective on shares of Janux Therapeutics in a report on Monday, March 11th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Buy” and an average target price of $61.33.

Janux Therapeutics Trading Up 7.3 %

The stock has a fifty day simple moving average of $41.91 and a 200-day simple moving average of $20.50. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -43.58 and a beta of 3.86.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.12. The company had revenue of $2.46 million during the quarter, compared to analysts’ expectations of $0.98 million. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its stake in Janux Therapeutics by 10,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after acquiring an additional 2,685 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $57,000. SG Americas Securities LLC acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $100,000. Old Well Partners LLC bought a new stake in shares of Janux Therapeutics during the third quarter valued at approximately $104,000. Finally, Corton Capital Inc. acquired a new position in shares of Janux Therapeutics in the third quarter valued at $111,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.